Aldeyra Therapeutics
ALDX
20 hedge funds and large institutions have $32.8M invested in Aldeyra Therapeutics in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 2 closing their positions.
143% more capital inflows, than outflows
Capital inflows: $217K | Capital outflows: $89.3K
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
0.18% more ownership
Funds ownership: 48.61% → 48.78% (+0.18%)
9% less funds holding
Funds holding: 22 → 20 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$73.8K |
| 2 |
PVI
Pura Vida Investments
New York
|
+$64.1K |
| 3 |
BlackRock Fund Advisors
San Francisco,
California
|
+$39.5K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$18.7K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$11.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FMA
FNY Managed Accounts
New York
|
-$39.1K |
| 2 |
AIC
AWM Investment Company
New York
|
-$30.5K |
| 3 |
JP Morgan Chase
New York
|
-$11K |
| 4 |
Morgan Stanley
New York
|
-$8.67K |
| 5 |
Millennium Management
New York
|
-$18 |
ALDX Hedge Fund Activity: Q4 2016 in Review
20 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q4 2016, worth a combined $32.8M — down 31% from $47.9M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ALDX and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $73.8K. The largest seller was FNY Managed Accounts, exiting entirely with an estimated $39.1K sold.
- 20 institutional investors held Aldeyra Therapeutics (ALDX) as of Q4 2016, down from 22 in Q3 2016.
- Funds reported $32.8M of Aldeyra Therapeutics stock for Q4 2016, down 31% quarter-over-quarter.
- 0 funds opened new Aldeyra Therapeutics positions in Q4 2016 and 2 closed out, a net change of -2 holders.
- The largest Aldeyra Therapeutics buyer in Q4 2016 was Vanguard Group, an estimated $73.8K added.
- The largest Aldeyra Therapeutics seller in Q4 2016 was FNY Managed Accounts, an estimated $39.1K sold.
Based on aggregated 13F filings for Q4 2016.